Back to Search Start Over

Hedgehog ligand and receptor cooperatively regulate EGFR stability and activity in non-small cell lung cancer.

Authors :
Huang A
Cheng J
Zhan Y
Zhou F
Xuan Y
Wang Y
Chen Q
Wang H
Xu X
Luo S
Cheng M
Source :
Cellular oncology (Dordrecht, Netherlands) [Cell Oncol (Dordr)] 2024 Aug; Vol. 47 (4), pp. 1405-1423. Date of Electronic Publication: 2024 Apr 03.
Publication Year :
2024

Abstract

Purpose: The hyperactivation of epidermal growth factor receptor (EGFR) plays a crucial role in non-small cell lung cancer (NSCLC). Hedgehog (Hh) signaling has been implicated in the tumorigenesis and progression of various cancers, however, its function in NSCLC cells remains controversial. Herein, we present a novel finding that challenges the current understanding of Hh signaling in tumor growth.<br />Methods: Expression of Hh ligands and receptor were assessed using TCGA datasets, immunoblotting and immunohistochemical. Biological function of Hh ligands and receptor in NSCLC were tested using colony formation, cell count kit-8 (CCK-8) and xenograft assays. Biochemical effect of Hh ligands and receptor on regulating EGFR stability and activity were checked via immunoblotting.<br />Results: Expression of Hh ligands and receptor was suppressed in NSCLC tissues, and the lower expression levels of these genes were associated with poor prognosis. Ptch1 binds to EGFR and facilitates its poly-ubiquitylation and degradation independent of downstream transcriptional signaling. Moreover, Hh ligands cooperate with Ptch1 to regulate the protein stability and activity of EGFR. This unique mechanism leads to a suppressive effect on NSCLC tumor growth.<br />Conclusion: Non-canonical Hh signaling pathway, involving cooperation between Hh ligands and their receptor Ptch1, facilitates the degradation of EGFR and attenuates its activity in NSCLC. These findings provide novel insights into the regulation of EGFR protein stability and activity, offer new diagnostic indicators for molecular typing of NSCLC and identify potential targets for targeted therapy of this challenging disease.<br /> (© 2024. Springer Nature Switzerland AG.)

Details

Language :
English
ISSN :
2211-3436
Volume :
47
Issue :
4
Database :
MEDLINE
Journal :
Cellular oncology (Dordrecht, Netherlands)
Publication Type :
Academic Journal
Accession number :
38568419
Full Text :
https://doi.org/10.1007/s13402-024-00938-6